Compliance Policy for NIOSH Approved Air-Purifying Respirators
AI-generated summary for informational purposes only. Not legal advice. See the original source for the authoritative text.
This draft guidance from the FDA aims to establish a compliance policy for various types of respirators approved by the CDC's NIOSH. It primarily addresses N95 and other similar respirators used for medical purposes and public health emergencies. Although not yet finalized, this guidance seeks to improve the effectiveness of resource utilization in line with existing policies, impacting manufacturers and healthcare providers.
AI-generated summary. May contain errors. Refer to official sources for legal decisions.
Key Changes
- Introduction of a compliance policy for NIOSH-approved respirators
- Focus on N95, surgical N95, and other reusable respirators for medical use
- Targets resource efficiency and effective use according to existing policies
Obligations
What this law requires
Manufacturers of surgical N95 respirators and N95 filtering facepiece respirators must comply with the premarket notification requirements under section 510(k) of the FD&C Act unless exempted by the FDA under certain conditions.
Manufacturers of non-surgical respirators, including powered air-purifying respirators (PAPRs) and reusable respirators, must ensure that their products are approved by NIOSH in accordance with 42 CFR part 84.
Manufacturers must submit comments on the draft guidance by June 22, 2026, to ensure that the FDA considers their input before finalizing the guidance.
Manufacturers must submit written/paper comments with confidential information in a two-copy format, where one copy contains the confidential information marked appropriately and the other is redacted for public viewing.
Submit requests for a single hard copy of the draft guidance document to the specified FDA office, including a self-addressed adhesive label for processing.